应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01548 金斯瑞生物科技
已收盘 12-19 16:08:47
9.790
-0.140
-1.41%
最高
9.960
最低
9.730
成交量
1,049万
今开
9.850
昨收
9.930
日振幅
2.32%
总市值
209.81亿
流通市值
209.81亿
总股本
21.43亿
成交额
1.03亿
换手率
0.49%
流通股本
21.43亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
南向资金12月18日净买入金斯瑞生物科技617.73万股 连续3日增持
市场透视 · 09:30
南向资金12月18日净买入金斯瑞生物科技617.73万股 连续3日增持
异动解读 | 金斯瑞生物科技股价盘中大涨5.17%,南向资金加仓及资金流入或是主因
异动解读 · 12-18 10:24
异动解读 | 金斯瑞生物科技股价盘中大涨5.17%,南向资金加仓及资金流入或是主因
金斯瑞生物科技盘中异动 股价大涨5.17%
市场透视 · 12-18 10:08
金斯瑞生物科技盘中异动 股价大涨5.17%
金斯瑞生物科技12月17日获南向资金加仓603.40万股
市场透视 · 12-18 09:30
金斯瑞生物科技12月17日获南向资金加仓603.40万股
金斯瑞生物科技12月16日获南向资金加仓589.20万股
市场透视 · 12-17 09:30
金斯瑞生物科技12月16日获南向资金加仓589.20万股
医药股多数承压 来凯医药(02105)跌近11% 机构指板块当前已经处于业绩、政策和资金三重反转的进程中
金吾财讯 · 12-16
医药股多数承压 来凯医药(02105)跌近11% 机构指板块当前已经处于业绩、政策和资金三重反转的进程中
金斯瑞生物科技(01548)下跌5.05%,报9.59元/股
金融界 · 12-16
金斯瑞生物科技(01548)下跌5.05%,报9.59元/股
金斯瑞生物科技盘中异动 股价大跌5.05%
市场透视 · 12-16
金斯瑞生物科技盘中异动 股价大跌5.05%
金斯瑞生物科技(01548)股价下跌5.05%,现价港币$9.59
阿斯达克财经 · 12-16
金斯瑞生物科技(01548)股价下跌5.05%,现价港币$9.59
金斯瑞生物科技盘中异动 股价大跌5.06%
市场透视 · 12-12
金斯瑞生物科技盘中异动 股价大跌5.06%
金斯瑞生物科技(01548)下跌5.15%,报10.68元/股
金融界 · 12-11
金斯瑞生物科技(01548)下跌5.15%,报10.68元/股
金斯瑞生物科技盘中异动 下午盘快速跳水5.15%报10.680港元
市场透视 · 12-11
金斯瑞生物科技盘中异动 下午盘快速跳水5.15%报10.680港元
金斯瑞生物科技(01548)因股份期权获行使而发行483万股
智通财经 · 12-10
金斯瑞生物科技(01548)因股份期权获行使而发行483万股
金斯瑞生物科技(01548):传奇生物宣布于2024年ASH年会上公布报告
智通财经 · 12-10
金斯瑞生物科技(01548):传奇生物宣布于2024年ASH年会上公布报告
异动解读 | 生物安全法案未入美国防授权法案 金斯瑞生物科技盘中大涨5.69%
异动解读 · 12-09
异动解读 | 生物安全法案未入美国防授权法案 金斯瑞生物科技盘中大涨5.69%
医药外包概念盘初向好 药明生物(02269)涨13.03% 美生物安全法案未被列入2025财年国防授权法案中
金吾财讯 · 12-09
医药外包概念盘初向好 药明生物(02269)涨13.03% 美生物安全法案未被列入2025财年国防授权法案中
金斯瑞生物科技盘中异动 股价大涨5.87%报11.900港元
市场透视 · 12-09
金斯瑞生物科技盘中异动 股价大涨5.87%报11.900港元
港股异动 | CRO概念股集体高开 生物安全法案未被列入美参众两院最终版NDAA
智通财经 · 12-09
港股异动 | CRO概念股集体高开 生物安全法案未被列入美参众两院最终版NDAA
南向资金12月3日净卖出金斯瑞生物科技174.60万股 连续3日减持
市场透视 · 12-04
南向资金12月3日净卖出金斯瑞生物科技174.60万股 连续3日减持
医药外包概念普升 药明生物(02269)涨7.48% 机构指CRO/CDMO明年可能逐步走出明显拐点
金吾财讯 · 12-03
医药外包概念普升 药明生物(02269)涨7.48% 机构指CRO/CDMO明年可能逐步走出明显拐点
暂无数据
公司概况
公司名称:
金斯瑞生物科技
所属市场:
SEHK
上市日期:
--
主营业务:
金斯瑞生物科技股份有限公司是一家主要从事生物科学研究及相关业务的香港投资控股公司。该公司通过四大分部运营。生命科学研究服务分部包括基因及多肽合成、脱氧核糖核酸及核酸引物合成、脱氧核糖核酸测序、定制抗体服务、蛋白质表达及稳定细胞株生产。临床前药物研发服务分部包括蛋白及抗体工程、体外药效研究及体内药效研究。生命科学研究目录产品分部提供抗体、重组蛋白、蛋白分离及分析仪器、分子生物学试剂、多肽、生物化学产品及稳定细胞株。工业合成生物产品分部开发及生产工业用酶。
发行价格:
--
{"stockData":{"symbol":"01548","market":"HK","secType":"STK","nameCN":"金斯瑞生物科技","latestPrice":9.79,"timestamp":1734595727013,"preClose":9.93,"halted":0,"volume":10493974,"delay":0,"floatShares":2143069983,"shares":2143069983,"eps":-0.35196188,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.14,"latestTime":"12-19 16:08:47","open":9.85,"high":9.96,"low":9.73,"amount":103273746,"amplitude":0.023162,"askPrice":9.79,"askSize":4000,"bidPrice":9.78,"bidSize":22000,"shortable":3,"etf":0,"ttmEps":-0.6511718324753892,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734658200000},"adr":0,"listingDate":1451404800000,"adjPreClose":9.93,"openAndCloseTimeList":[[1734571800000,1734580800000],[1734584400000,1734595200000]],"volumeRatio":0.552222,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01548/tweets","defaultTab":"tweets","newsList":[{"id":"2492160033","title":"南向资金12月18日净买入金斯瑞生物科技617.73万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2492160033","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492160033?lang=zh_cn&edition=full","pubTime":"2024-12-19 09:30","pubTimestamp":1734571817,"startTime":"0","endTime":"0","summary":"12月18日, 南向资金增持金斯瑞生物科技617.73万股,连续3日增持。截止当日收盘,港股通共持有金斯瑞生物科技54248.39万股,占流通股25.30%。港股通增持金额前五个股分别为中国移动、工商银行、建设银行、中国海洋石油、中国平安。金斯瑞生物科技近5个交易日下跌7.02%,港股通累计增持1795.93万股;近20个交易日下跌7.54%,港股通累计增持2459.35万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219093347ab8327e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219093347ab8327e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000306701.USD","01548","HK0000320264.USD","BK1141","HK0000306685.HKD","BK1583","HK0000320223.HKD","BK1576"],"gpt_icon":0},{"id":"1150975661","title":"异动解读 | 金斯瑞生物科技股价盘中大涨5.17%,南向资金加仓及资金流入或是主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1150975661","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150975661?lang=zh_cn&edition=full","pubTime":"2024-12-18 10:24","pubTimestamp":1734488686,"startTime":"0","endTime":"0","summary":"12月18日早盘,金斯瑞生物科技(01548.HK)股价出现大涨,引发市场广泛关注。据最新交易数据显示,该股盘中一度大涨5.17%,报10.18港元,成交额约6262万港元。\n\n分析人士认为,推动金斯瑞生物科技股价大涨的主要原因或与资金流向有关。数据显示,12月17日南向资金净增持该股603.4万股,港股通累计持股量达到5.363亿股,占流通股比例达25.01%。同时,资金流向数据显示,当日该股资金净流入781.86万港元。\n\n除资金面外,市场人士预期金斯瑞生物科技在生物科技领域的发展前景广阔,未来业绩有望持续向好,这也可能助推股价上涨。但具体的利好消息尚待公司进一步公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 金斯瑞生物科技股价盘中大涨5.17%,南向资金加仓及资金流入或是主因","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01548"],"gpt_icon":0},{"id":"2492976944","title":"金斯瑞生物科技盘中异动 股价大涨5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492976944","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492976944?lang=zh_cn&edition=full","pubTime":"2024-12-18 10:08","pubTimestamp":1734487739,"startTime":"0","endTime":"0","summary":"2024年12月18日早盘10时08分,金斯瑞生物科技股票出现波动,股价急速上涨5.17%。截至发稿,该股报10.180港元/股,成交量626.2万股,换手率0.29%,振幅3.93%。资金方面,该股资金流入3084.97万港元,流出2303.11万港元。金斯瑞生物科技股票所在的生物技术行业中,整体涨幅为0.53%。金斯瑞生物科技公司简介:金斯瑞生物科技股份有限公司是一家主要从事生物科学研究及相关业务的香港投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218100859ab8093d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218100859ab8093d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000306685.HKD","BK1141","HK0000320264.USD","BK1576","BK1583","HK0000320223.HKD","01548","HK0000306701.USD"],"gpt_icon":0},{"id":"2492616949","title":"金斯瑞生物科技12月17日获南向资金加仓603.40万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492616949","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492616949?lang=zh_cn&edition=full","pubTime":"2024-12-18 09:30","pubTimestamp":1734485418,"startTime":"0","endTime":"0","summary":"12月17日, 南向资金增持金斯瑞生物科技603.40万股。截止当日收盘,港股通共持有金斯瑞生物科技53630.66万股,占流通股25.01%。金斯瑞生物科技近5个交易日下跌14.03%,港股通累计增持1322.60万股;近20个交易日下跌9.19%,港股通累计增持2918.23万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218093428a1f73406&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241218093428a1f73406&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","HK0000320264.USD","BK1576","BK1141","01548","HK0000320223.HKD","HK0000306685.HKD","HK0000306701.USD"],"gpt_icon":0},{"id":"2492674817","title":"金斯瑞生物科技12月16日获南向资金加仓589.20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492674817","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492674817?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:30","pubTimestamp":1734399017,"startTime":"0","endTime":"0","summary":"12月16日, 南向资金增持金斯瑞生物科技589.20万股。截止当日收盘,港股通共持有金斯瑞生物科技53027.26万股,占流通股24.73%。金斯瑞生物科技近5个交易日下跌16.75%,港股通累计增持561.00万股;近20个交易日下跌9.57%,港股通累计增持2028.90万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217093156a1f46aab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217093156a1f46aab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000306701.USD","BK1141","HK0000306685.HKD","HK0000320223.HKD","01548","HK0000320264.USD","BK1576","BK1583"],"gpt_icon":0},{"id":"2491630509","title":"医药股多数承压 来凯医药(02105)跌近11% 机构指板块当前已经处于业绩、政策和资金三重反转的进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2491630509","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491630509?lang=zh_cn&edition=full","pubTime":"2024-12-16 14:56","pubTimestamp":1734332198,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药股多数承压,来凯医药 跌10.94%,康诺亚跌6.07%,金斯瑞生物科技跌5.54%,科伦博泰生物跌4.96%,康方生物跌4.4%,药明生物跌3.15%。国金证券发研指,医药板块当前已经处于业绩、政策和资金三重反转的进程之中,对2025年医药板块上市公司营收利润增速回升、板块行情复苏有充分信心。医保局将指导各地及中选企业做好中选结果落地实施工作,确保全国患者于2025年4月用上本次集采中选产品。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1949709","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0043850808.USD","LU0516423091.SGD","BK1576","LU0456827905.SGD","02162","06990","LU0348735423.USD","LU0516422952.EUR","HK0000306685.HKD","IE00B0JY6N72.USD","LU0417516571.SGD","LU0823426308.USD","LU0359201612.USD","LU1242518857.USD","LU0572944931.SGD","LU1720050803.USD","HK0000320223.HKD","SG9999002463.SGD","LU0326950275.SGD","01548","09939","LU0051755006.USD","LU0456846285.SGD","LU0181495838.USD","09926","LU0516422366.SGD","LU1880383366.USD","LU0516423174.USD","IE00B5MMRT66.SGD","LU0588546209.SGD","BK1583","LU0320764599.SGD","LU0348825331.USD","LU0979878070.USD","HK0000306701.USD","BK1521","02105","LU0348784397.USD","LU2488822045.USD","LU0348783233.USD","LU1242518931.SGD","LU0140636845.USD","02269","BK1587","LU2039709279.SGD","LU0307460666.USD","LU0359202008.SGD","159938","BK1574","LU0823426480.USD"],"gpt_icon":1},{"id":"2491634099","title":"金斯瑞生物科技(01548)下跌5.05%,报9.59元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2491634099","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491634099?lang=zh_cn&edition=full","pubTime":"2024-12-16 14:10","pubTimestamp":1734329450,"startTime":"0","endTime":"0","summary":"12月16日,金斯瑞生物科技(01548)盘中下跌5.05%,截至14:10,报9.59元/股,成交1.52亿元。金斯瑞生物科技股份有限公司是全球的生命科学研发与生产服务提供商,以DNA合成技术为基础,主要服务包含生命科学服务及产品业务、生物制剂合约开发及生产、工业合成产品业务、以及综合性全球细胞疗法。至2024年6月30日,公司全球拥有超过6900名员工,已有超103,600篇学术期刊引述了其服务及产品,拥有超过300项授权专利与900多项专利申请,并积极致力于成为全球最受信赖的生物科技公司。截至2024年中报,金斯瑞生物科技营业总收入40.01亿元、净利润-12.48亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/16141046413198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","HK0000320264.USD","BK1576","BK1141","01548","HK0000320223.HKD","HK0000306685.HKD","HK0000306701.USD"],"gpt_icon":0},{"id":"2491632340","title":"金斯瑞生物科技盘中异动 股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491632340","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491632340?lang=zh_cn&edition=full","pubTime":"2024-12-16 14:10","pubTimestamp":1734329444,"startTime":"0","endTime":"0","summary":"2024年12月16日下午盘14时10分,金斯瑞生物科技股票出现异动,股价大幅下跌5.05%。截至发稿,该股报9.590港元/股,成交量1548.53万股,换手率0.72%,振幅6.44%。资金方面,该股资金流入6120.87万港元,流出6234.05万港元。金斯瑞生物科技股票所在的生物技术行业中,整体跌幅为1.15%。金斯瑞生物科技公司简介:金斯瑞生物科技股份有限公司是一家主要从事生物科学研究及相关业务的香港投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216141044984c6390&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216141044984c6390&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000320264.USD","BK1141","01548","HK0000306701.USD","HK0000306685.HKD","BK1583","HK0000320223.HKD","BK1576"],"gpt_icon":0},{"id":"2491632657","title":"金斯瑞生物科技(01548)股价下跌5.05%,现价港币$9.59","url":"https://stock-news.laohu8.com/highlight/detail?id=2491632657","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491632657?lang=zh_cn&edition=full","pubTime":"2024-12-16 14:10","pubTimestamp":1734329400,"startTime":"0","endTime":"0","summary":"[下跌股]金斯瑞生物科技(01548) 股价在下午02:10比前收市价下跌5.05%,现股价为港币$9.59。至目前为止,今日最高价为$10.24,而最低价为$9.59。总成交量为1.548千万股,总成交金额为港币$1.519亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152743541_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152743541_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2412161538/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1141","HK0000320223.HKD","HK0000306685.HKD","BK1583","BK1576","HK0000306701.USD","01548","HK0000320264.USD"],"gpt_icon":0},{"id":"2490841809","title":"金斯瑞生物科技盘中异动 股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490841809","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490841809?lang=zh_cn&edition=full","pubTime":"2024-12-12 09:51","pubTimestamp":1733968264,"startTime":"0","endTime":"0","summary":"2024年12月12日早盘09时51分,金斯瑞生物科技股票出现波动,股价大幅下挫5.06%。截至发稿,该股报10.140港元/股,成交量796.4万股,换手率0.37%,振幅3.37%。资金方面,该股资金流入1814.39万港元,流出4616.26万港元。金斯瑞生物科技股票所在的生物技术行业中,整体涨幅为0.11%。金斯瑞生物科技公司简介:金斯瑞生物科技股份有限公司是一家主要从事生物科学研究及相关业务的香港投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121209510495e91459&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121209510495e91459&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000306701.USD","01548","HK0000320264.USD","BK1141","HK0000306685.HKD","BK1583","HK0000320223.HKD","BK1576"],"gpt_icon":0},{"id":"2490547000","title":"金斯瑞生物科技(01548)下跌5.15%,报10.68元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490547000","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490547000?lang=zh_cn&edition=full","pubTime":"2024-12-11 13:21","pubTimestamp":1733894515,"startTime":"0","endTime":"0","summary":"12月11日,金斯瑞生物科技(01548)盘中下跌5.15%,截至13:21,报10.68元/股,成交1.67亿元。金斯瑞生物科技股份有限公司是全球的生命科学研发与生产服务提供商,以DNA合成技术为基础,主要服务包含生命科学服务及产品业务、生物制剂合约开发及生产、工业合成产品业务、以及综合性全球细胞疗法。至2024年6月30日,公司全球拥有超过6900名员工,已有超103,600篇学术期刊引述了其服务及产品,拥有超过300项授权专利与900多项专利申请,并积极致力于成为全球最受信赖的生物科技公司。截至2024年中报,金斯瑞生物科技营业总收入40.01亿元、净利润-12.48亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/11132146248147.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HK0000306701.USD","BK1141","HK0000306685.HKD","HK0000320223.HKD","01548","HK0000320264.USD","BK1576","BK1583"],"gpt_icon":0},{"id":"2490000120","title":"金斯瑞生物科技盘中异动 下午盘快速跳水5.15%报10.680港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490000120","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490000120?lang=zh_cn&edition=full","pubTime":"2024-12-11 13:15","pubTimestamp":1733894108,"startTime":"0","endTime":"0","summary":"2024年12月11日下午盘13时15分,金斯瑞生物科技股票出现异动,股价大幅下挫5.15%。截至发稿,该股报10.680港元/股,成交量1497.74万股,换手率0.70%,振幅3.37%。资金方面,该股资金流入5798.65万港元,流出6811.1万港元。金斯瑞生物科技股票所在的生物技术行业中,整体跌幅为0.48%。金斯瑞生物科技公司简介:金斯瑞生物科技股份有限公司是一家主要从事生物科学研究及相关业务的香港投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211131508ab6e97dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211131508ab6e97dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000320223.HKD","HK0000306685.HKD","HK0000306701.USD","BK1141","BK1583","BK1576","HK0000320264.USD","01548"],"gpt_icon":0},{"id":"2490736098","title":"金斯瑞生物科技(01548)因股份期权获行使而发行483万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490736098","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490736098?lang=zh_cn&edition=full","pubTime":"2024-12-10 18:36","pubTimestamp":1733827007,"startTime":"0","endTime":"0","summary":"智通财经APP讯,金斯瑞生物科技(01548)发布公告,该公司于2024年12月10日根据2015年7月15日通过的上市前股份期权计划行使的股份期权而发行483万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222898.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306701.USD","01548","HK0000320264.USD","BK1141","HK0000306685.HKD","BK1583","HK0000320223.HKD","BK1576"],"gpt_icon":0},{"id":"2490940064","title":"金斯瑞生物科技(01548):传奇生物宣布于2024年ASH年会上公布报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2490940064","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490940064?lang=zh_cn&edition=full","pubTime":"2024-12-10 17:14","pubTimestamp":1733822078,"startTime":"0","endTime":"0","summary":"智通财经APP讯,金斯瑞生物科技 发布公告,于2024年12月10日,传奇生物科技股份有限公司已发布新闻稿,公布了3期研究CARTITUDE-4最新数据。MRD阴性率是多发性骨髓瘤患者生存期延长的重要预后标志。MRD阴性率的研究结果已在加利福尼亚州圣地牙哥举行的第66届美国血液学会年会暨展览会上以口头报告的形式发表。研究进行了随机分组,208名患者接受CARVYKTI治疗,211名患者接受标准疗法。截至目前,CARVYKTI已在全球五个国家推出,治疗患者人数逾4500名。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK1583","BK4505","BK4109","BK1141","HK0000306685.HKD","HK0000320223.HKD","LU2463526074.USD","01548","LEGN","BK4139","ASH","BK4585","HK0000320264.USD","HK0000306701.USD","BK4588"],"gpt_icon":0},{"id":"1100690523","title":"异动解读 | 生物安全法案未入美国防授权法案 金斯瑞生物科技盘中大涨5.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100690523","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100690523?lang=zh_cn&edition=full","pubTime":"2024-12-09 09:38","pubTimestamp":1733708302,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技(01548)今日盘中大涨5.69%,引起市场广泛关注。主要原因包括以下几点:\n\n首先,针对美国生物安全法案的立法进展有了新的进展。美国国会参众两院军事委员会公布的2025财年国防授权法案(NDAA)最终协议文本显示,生物安全法案未被列入其中。这意味着生物安全法案试图通过加入NDAA的立法路径失败,在一定程度上减轻了对生物医药外包行业的政策风险压力。\n\n同时,市场对生物医药外包行业的整体前景保持乐观。分析师认为,近年来随着海外投融资逐步恢复,下游需求保持旺盛,加上新兴细分领域不断发展,行业将持续受益并具有广阔的成长空间。作为领先企业,金斯瑞生物科技将从行业良好发展趋势中获益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01548"],"gpt_icon":0},{"id":"2490762754","title":"医药外包概念盘初向好 药明生物(02269)涨13.03% 美生物安全法案未被列入2025财年国防授权法案中","url":"https://stock-news.laohu8.com/highlight/detail?id=2490762754","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490762754?lang=zh_cn&edition=full","pubTime":"2024-12-09 09:34","pubTimestamp":1733708065,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药外包概念盘初向好,截至发稿,药明生物 涨13.03%,药明康德涨11.72%,康龙化成涨9.14%,金斯瑞生物科技涨4.98%,泰格医药涨4.87%。消息面上,美国当地时间12月7日,美国国会参众两院军事委员会公布的2025财年国防授权法案最终协议文本显示,生物安全法案未被列入其中。摩根士丹利称,美国2025财年国防授权法案没有生物安全法案或任何药明系的名字,这对药明系和其他具有重大海外收入敞口的中国CRO/CDMO公司是一个积极的进展。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"810550c4387583238de39f78e3a07e4f","isJumpTheme":false,"source_url":"1949198","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348735423.USD","LU0456827905.SGD","LU0051755006.USD","01548","LU0181495838.USD","LU2045819591.USD","SG9999002562.SGD","LU0043850808.USD","02269","LU0307460666.USD","03759","LU0516422366.SGD","LU0979878070.USD","LU1720050803.USD","LU0856984785.SGD","BK1515","HK0000320264.USD","LU0823426308.USD","LU0456846285.SGD","LU1046422090.SGD","LU0516422952.EUR","LU0348825331.USD","02359","LU0823426480.USD","LU0359202008.SGD","BK1576","BK1610","159938","LU0359201612.USD","03347","BK1141","BK1574","LU0572944931.SGD","LU0708995583.HKD","09939","LU0516423174.USD","SG9999002463.SGD","LU0516423091.SGD","LU1242518931.SGD","BK1161","HK0000306685.HKD","LU0588546209.SGD","LU0052750758.USD","LU0417516902.SGD","LU0320764599.SGD","LU0326950275.SGD","LU2242644610.SGD","HK0000320223.HKD","LU2125910500.SGD","LU0140636845.USD"],"gpt_icon":1},{"id":"2490576714","title":"金斯瑞生物科技盘中异动 股价大涨5.87%报11.900港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490576714","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490576714?lang=zh_cn&edition=full","pubTime":"2024-12-09 09:30","pubTimestamp":1733707806,"startTime":"0","endTime":"0","summary":"2024年12月09日早盘09时30分,金斯瑞生物科技股票出现异动,股价急速拉升5.87%。截至发稿,该股报11.900港元/股,成交量85.4万股,换手率0.04%,振幅2.31%。资金方面,该股资金流入66.184万港元,流出275.3万港元。金斯瑞生物科技股票所在的生物技术行业中,整体涨幅为1.93%。金斯瑞生物科技公司简介:金斯瑞生物科技股份有限公司是一家主要从事生物科学研究及相关业务的香港投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209093006ab686a4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209093006ab686a4e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000320264.USD","BK1141","HK0000320223.HKD","HK0000306685.HKD","BK1583","01548","HK0000306701.USD","BK1576"],"gpt_icon":0},{"id":"2490762502","title":"港股异动 | CRO概念股集体高开 生物安全法案未被列入美参众两院最终版NDAA","url":"https://stock-news.laohu8.com/highlight/detail?id=2490762502","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490762502?lang=zh_cn&edition=full","pubTime":"2024-12-09 09:23","pubTimestamp":1733707405,"startTime":"0","endTime":"0","summary":"消息面上,当地时间12月7日,美国国会参众两院军事委员会公布了2025财年国防授权法案最终协议文本,该版本兼顾了众议院以及参议院两方的提案。NDAA最新版本显示,生物安全法案未被列入其中。按照流程,该版本要获得美国总统签字之后才能生效。招银国国际认为,这意味着生物安全法案试图通过加入NDAA的立法路径失败。生物安全法案仍可以推进单独立法,但考虑到仅剩两周窗口期,该行认为单独立法的成功率极低。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0140636845.USD","LU0516422952.EUR","LU0516423091.SGD","HK0000320223.HKD","LU1242518931.SGD","02269","HK0000306685.HKD","LU0052750758.USD","SG9999002463.SGD","LU1046422090.SGD","BK1589","LU0320764599.SGD","LU0359201612.USD","BK1610","NDAA","HK0000320264.USD","LU0417516902.SGD","LU2242644610.SGD","LU0979878070.USD","LU0307460666.USD","LU0588546209.SGD","BK1521","LU0708995583.HKD","02359","LU0823426308.USD","LU0348825331.USD","BK1583","LU2125910500.SGD","LU0417516738.SGD","LU0039217434.USD","LU0456846285.SGD","LU2045819591.USD","06127","HK0000306701.USD","LU0516423174.USD","LU0823426480.USD","LU0181495838.USD","LU0348735423.USD","IE00B0JY6N72.USD","LU0516422440.USD","LU1794554557.SGD","LU0572944931.SGD","LU0327786744.USD","LU0856984785.SGD","LU1720050803.USD","03759","LU0516422366.SGD","LU1688375341.USD","01548","BK1141"],"gpt_icon":1},{"id":"2488900109","title":"南向资金12月3日净卖出金斯瑞生物科技174.60万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2488900109","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488900109?lang=zh_cn&edition=full","pubTime":"2024-12-04 09:30","pubTimestamp":1733275811,"startTime":"0","endTime":"0","summary":"12月3日,南向资金减持金斯瑞生物科技174.60万股连续3日减持。截止当日收盘,港股通共持有金斯瑞生物科技52790.26万股,占流通股24.68%。港股通减持金额前五个股分别为小米集团-W、中银香港、快手-W、金山云、泡泡玛特。金斯瑞生物科技近5个交易日上涨4.77%,港股通累计减持218.77万股;近20个交易日下跌9.26%,港股通累计增持2868.70万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204093123abf4254f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204093123abf4254f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","HK0000320223.HKD","BK1141","01548","BK1583","HK0000306701.USD","HK0000320264.USD","HK0000306685.HKD"],"gpt_icon":0},{"id":"2488996427","title":"医药外包概念普升 药明生物(02269)涨7.48% 机构指CRO/CDMO明年可能逐步走出明显拐点","url":"https://stock-news.laohu8.com/highlight/detail?id=2488996427","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488996427?lang=zh_cn&edition=full","pubTime":"2024-12-03 15:41","pubTimestamp":1733211718,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药外包概念普升,药明生物 涨7.48%,药明康德涨6.12%,康龙化成涨2.8%,金斯瑞生物科技涨1.87%,凯莱英涨1.44%。板块内部来看,在医保预付金、医保目录发布等政策催化下,医药商业、创新药子板块均有不错表现。该行表示,今年来看,原料药、低耗、上游的部分个股率先表现出了一定改善,展望明年,原料药、低耗的趋势有望持续,CRO/CDMO、上游、ICL、设备招投标可能逐步走出明显拐点。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MzQyYjVhODQ3ZWY1M2M1MGY5NWIyMTYzODE1MzIxNzE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1948872","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","CDMO","HK0000306685.HKD","LU0417516738.SGD","LU1688375341.USD","LU0359201612.USD","BK1610","02359","159938","HK0000306701.USD","SG9999002463.SGD","LU0039217434.USD","LU0456846285.SGD","01548","IE00B0JY6N72.USD","LU0572944931.SGD","LU0823426480.USD","LU0327786744.USD","BK1574","LU0516422952.EUR","BK1576","LU0181495838.USD","02269","BK1583","LU0856984785.SGD","LU0140636845.USD","HK0000320264.USD","LU0320764599.SGD","BK1191","LU0052750758.USD","LU1794554557.SGD","BK4139","06821","LU0051755006.USD","BK1589","LU0979878070.USD","HK0000320223.HKD","09939","LU0417516902.SGD","LU0359202008.SGD","LU0456827905.SGD","LU0516423091.SGD","BK1161","SG9999002562.SGD","LU2242644610.SGD","LU0588546209.SGD","LU1720050803.USD","03759","LU1046422090.SGD","LU0516422440.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genscript.com","stockEarnings":[{"period":"1week","weight":-0.0702},{"period":"1month","weight":-0.0685},{"period":"3month","weight":-0.1683},{"period":"6month","weight":0.1696},{"period":"1year","weight":-0.5096},{"period":"ytd","weight":-0.5}],"compareEarnings":[{"period":"1week","weight":-0.0144},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.1018},{"period":"1year","weight":0.2035},{"period":"ytd","weight":0.1653}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"金斯瑞生物科技股份有限公司是一家主要从事生物科学研究及相关业务的香港投资控股公司。该公司通过四大分部运营。生命科学研究服务分部包括基因及多肽合成、脱氧核糖核酸及核酸引物合成、脱氧核糖核酸测序、定制抗体服务、蛋白质表达及稳定细胞株生产。临床前药物研发服务分部包括蛋白及抗体工程、体外药效研究及体内药效研究。生命科学研究目录产品分部提供抗体、重组蛋白、蛋白分离及分析仪器、分子生物学试剂、多肽、生物化学产品及稳定细胞株。工业合成生物产品分部开发及生产工业用酶。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":-0.012915},{"month":2,"riseRate":0.555556,"avgChangeRate":0.078892},{"month":3,"riseRate":0.555556,"avgChangeRate":-0.061679},{"month":4,"riseRate":0.555556,"avgChangeRate":0.055583},{"month":5,"riseRate":0.444444,"avgChangeRate":0.056395},{"month":6,"riseRate":0.555556,"avgChangeRate":0.032355},{"month":7,"riseRate":0.555556,"avgChangeRate":0.066374},{"month":8,"riseRate":0.333333,"avgChangeRate":0.112385},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.076829},{"month":10,"riseRate":0.666667,"avgChangeRate":0.110695},{"month":11,"riseRate":0.666667,"avgChangeRate":0.058325},{"month":12,"riseRate":0.333333,"avgChangeRate":0.066202}],"exchange":"SEHK","name":"金斯瑞生物科技","nameEN":"GENSCRIPT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金斯瑞生物科技(01548)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金斯瑞生物科技,01548,金斯瑞生物科技股票,金斯瑞生物科技股票老虎,金斯瑞生物科技股票老虎国际,金斯瑞生物科技行情,金斯瑞生物科技股票行情,金斯瑞生物科技股价,金斯瑞生物科技股市,金斯瑞生物科技股票价格,金斯瑞生物科技股票交易,金斯瑞生物科技股票购买,金斯瑞生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金斯瑞生物科技(01548)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}